BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

KCI launches ABTHERA Therapy in Japan

February 21, 2019 | News

ABTHERAÃ¢â??Â¢ Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings.



KCI, an Acelity Company, recently announced the launch of ABTHERA™ Open Abdomen Negative Pressure Therapy in Japan, expanding access to the Company's surgical portfolio in the country.

ABTHERA™ Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary.

ABTHERA™ Therapy is supported by robust clinical evidence and is associated with improved outcomes, including increased patient survival, improved primary fascial closure rates, lower intensive care unit stays when compared to Barker's vacuum-packing technique (BVPT).

"When dealing with patients managed with damage control for severe abdominal hemorrhage, abdominal compartment syndrome or severe peritonitis, using ABTHERA™ Therapy has been shown to be associated with proven patient outcomes," said Dr. Demetrios Demetriades, Professor of Surgery, Keck USC School of Medicine and the Director of the USC Division of Trauma, Emergency Surgery and Surgical Intensive Care Unit. "With the introduction of ABTHERA™ Therapy in Japan, clinicians now have a clinically demonstrated solution for a previously unmet, significant need, that manages the open abdomen at critical times, helping to achieve primary fascial closure more quickly."